{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:13:16Z","timestamp":1792181596998,"version":"4.4.0"},"reference-count":123,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-C&T-B-080"],"award-info":[{"award-number":["2021-I2M-C&T-B-080"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-017"],"award-info":[{"award-number":["2021-I2M-1-017"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["22HHXBSS00036"],"award-info":[{"award-number":["22HHXBSS00036"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["21JCZDJC01170"],"award-info":[{"award-number":["21JCZDJC01170"]}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["2021-I2M-C&T-B-080"],"award-info":[{"award-number":["2021-I2M-C&T-B-080"]}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["2021-I2M-1-017"],"award-info":[{"award-number":["2021-I2M-1-017"]}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["22HHXBSS00036"],"award-info":[{"award-number":["22HHXBSS00036"]}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["21JCZDJC01170"],"award-info":[{"award-number":["21JCZDJC01170"]}]},{"name":"Tianjin Municipal Science and Technology Commission Grant","award":["2021-I2M-C&T-B-080"],"award-info":[{"award-number":["2021-I2M-C&T-B-080"]}]},{"name":"Tianjin Municipal Science and Technology Commission Grant","award":["2021-I2M-1-017"],"award-info":[{"award-number":["2021-I2M-1-017"]}]},{"name":"Tianjin Municipal Science and Technology Commission Grant","award":["22HHXBSS00036"],"award-info":[{"award-number":["22HHXBSS00036"]}]},{"name":"Tianjin Municipal Science and Technology Commission Grant","award":["21JCZDJC01170"],"award-info":[{"award-number":["21JCZDJC01170"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>The incidence rate of invasive mucormycosis (IM) in patients with hematological malignancies (HMs) is increasing year by year, ranging from 0.07% to 4.29%, and the mortality rate is mostly higher than 50%. With the ongoing pandemic of COVID-19, COVID-19-associated mucormycosis (CAM) also became a global health threat. Patients with high risk factors such as active HMs, relapsed\/refractory leukemia, prolonged neutropenia may still develop breakthrough mucormycosis (BT-MCR) even under the prophylaxis of Mucorales-active antifungals, and such patients often have higher mortality. Rhizopus spp. is the most common genus associated with IM, followed by Mucor spp. and Lichtheimia spp. Pulmonary mucormycosis (PM) is the most common form of IM in patients with HMs, followed by rhino-orbital-cerebral mucormycosis (ROCM) and disseminated mucormycosis. The prognosis of IM patients with neutrophil recovery, localized IM and receiving early combined medical\u2013surgical therapy is usually better. As for management of the disease, risk factors should be eliminated firstly. Liposome amphotericin B (L-AmB) combined with surgery is the initial treatment scheme of IM. Those who are intolerant to L-AmB can choose intravenous formulations or tablets of isavuconazole or posaconazole. Patients who are refractory to monotherapy can turn to combined antifungals therapy.<\/jats:p>","DOI":"10.3390\/jof9050592","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T10:08:55Z","timestamp":1684490935000},"page":"592","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies"],"prefix":"10.3390","volume":"9","author":[{"given":"Nuobing","family":"Yang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/myc.13033","article-title":"A population-based analysis of attributable hospitalisation costs of invasive fungal diseases in haematological malignancy patients using data linkage of state-wide registry and costing databases: 2009\u20132015","volume":"63","author":"Valentine","year":"2020","journal-title":"Mycoses"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2141.1997.3983214.x","article-title":"Mucormycosis in patients with haematological malignancies: A retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto)","volume":"99","author":"Pagano","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_3","first-page":"32","article-title":"Epidemiology and clinical manifestation of fungal infection related to Mucormycosis in hematologic malignancies","volume":"8","author":"Noorifard","year":"2015","journal-title":"J. Med. Life"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/myc.12081","article-title":"Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: A 20-year autopsy study","volume":"56","author":"Lewis","year":"2013","journal-title":"Mycoses"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.12703\/P6-81","article-title":"Epidemiology of invasive fungal diseases on the basis of autopsy reports","volume":"6","author":"Dignani","year":"2014","journal-title":"F1000Prime Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Guinea, J., Escribano, P., Vena, A., Munoz, P., Martinez-Jimenez, M.D.C., Padilla, B., and Bouza, E. (2017). Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179136"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001\u20132006","volume":"17","author":"Park","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Sung, A.H., Rubinstein, E., Benigno, M., Chambers, R., Patino, N., and Aram, J.A. (2022). Characterizing patients with rare mucormycosis infections using real-world data. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07115-w"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/myc.12915","article-title":"Overview and outcome of mucormycosis among children with cancer: Report from the Children\u2019s Cancer Hospital Egypt","volume":"62","author":"Madney","year":"2019","journal-title":"Mycoses"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/myc.12149","article-title":"Prospective antifungal therapy (PATH) alliance((R)): Focus on mucormycosis","volume":"57","author":"Kontoyiannis","year":"2014","journal-title":"Mycoses"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"944.e9","DOI":"10.1016\/j.cmi.2019.11.021","article-title":"A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India","volume":"26","author":"Patel","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/03007995.2020.1846510","article-title":"The disease burden of mucormycosis in Japan: Results from a systematic literature review and retrospective database study","volume":"37","author":"Ueno","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A global analysis of mucormycosis in France: The RetroZygo Study (2005\u20132007)","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Valentine, J.C., Morrissey, C.O., Tacey, M.A., Liew, D., Patil, S., Peleg, A.Y., and Ananda-Rajah, M.R. (2019). A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005\u20132016. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3901-y"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/bmt.2015.263","article-title":"Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: A CIBMTR infection and immune reconstitution analysis","volume":"51","author":"Riches","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","article-title":"Zygomycosis in the 1990s in a tertiary-care cancer center","volume":"30","author":"Kontoyiannis","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E396","DOI":"10.1111\/j.1469-0691.2012.03908.x","article-title":"Mucormycosis after allogeneic haematopoietic stem cell transplantation: A French Multicentre Cohort Study (2003\u20132008)","volume":"18","author":"Xhaard","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/myc.12862","article-title":"Invasive mucormycosis in children with cancer: A retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association","volume":"62","author":"Muggeo","year":"2019","journal-title":"Mycoses"},{"key":"ref_19","first-page":"207","article-title":"Mucormycosis in hematologic patients","volume":"89","author":"Pagano","year":"2004","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/cid\/cix130","article-title":"Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis","volume":"64","author":"Lamoth","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Axell-House, D.B., Wurster, S., Jiang, Y., Kyvernitakis, A., Lewis, R.E., Tarrand, J.J., Raad, I.I., and Kontoyiannis, D.P. (2021). Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. J. Fungi, 7.","DOI":"10.3390\/jof7030217"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijid.2021.06.066","article-title":"Clinical and microbiological features and outcomes of mucormycosis in critically ill patients","volume":"109","author":"Rothe","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"O952","DOI":"10.1111\/1469-0691.12688","article-title":"Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: A 4-year study","volume":"20","author":"Lerolle","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_25","first-page":"1610","article-title":"Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole","volume":"67","author":"Rausch","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"111643","DOI":"10.1016\/j.envres.2021.111643","article-title":"Mucormycosis: An opportunistic pathogen during COVID-19","volume":"201","author":"Mahalaxmi","year":"2021","journal-title":"Environ. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102148","DOI":"10.1016\/j.tmaid.2021.102148","article-title":"COVID-19-associated mucormycosis: Case report and systematic review","volume":"44","author":"Dilek","year":"2021","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/myc.13338","article-title":"COVID-19-associated mucormycosis: An updated systematic review of literature","volume":"64","author":"Pal","year":"2021","journal-title":"Mycoses"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/myc.13353","article-title":"Mucormycosis and COVID-19: An epidemic within a pandemic in India","volume":"64","author":"Selarka","year":"2021","journal-title":"Mycoses"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jinf.2021.12.039","article-title":"Risk factors for Coronavirus disease-associated mucormycosis","volume":"84","author":"Arora","year":"2022","journal-title":"J. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cmi.2016.01.005","article-title":"Mucormycosis in Australia: Contemporary epidemiology and outcomes","volume":"22","author":"Kennedy","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jpids\/piz007","article-title":"Pediatric Mucormycosis: A 10-Year Systematic Review of Reported Cases and Review of the Literature","volume":"8","author":"Otto","year":"2019","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"490.e1","DOI":"10.1016\/j.cmi.2014.12.021","article-title":"Invasive infections due to filamentous fungi other than Aspergillus: Epidemiology and determinants of mortality","volume":"21","author":"Slavin","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Pana, Z.D., Seidel, D., Skiada, A., Groll, A.H., Petrikkos, G., Cornely, O.A., Roilides, E., and Collaborators of Zygomyco.net and\/or FungiScope\u2122 Registries (2016). Invasive mucormycosis in children: An epidemiologic study in European and non-European countries based on two registries. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-2005-1"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1742-1241.2006.01145.x","article-title":"Mucormycosis-associated fungal infections in patients with haematologic malignancies","volume":"63","author":"Kara","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1093\/mmy\/myy116","article-title":"Contrasts between mucormycosis and aspergillosis in oncohematological patients","volume":"57","author":"Klimko","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"684.e11","DOI":"10.1016\/j.cmi.2015.03.019","article-title":"Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis","volume":"21","author":"Jung","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/430710","article-title":"Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer","volume":"41","author":"Chamilos","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3174\/ajnr.A6037","article-title":"The Black Turbinate Sign, A Potential Diagnostic Pitfall: Evaluation of the Normal Enhancement Patterns of the Nasal Turbinates","volume":"40","author":"Han","year":"2019","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jinf.2014.07.027","article-title":"The prognostic value of gadolinium-enhanced magnetic resonance imaging in acute invasive fungal rhinosinusitis","volume":"70","author":"Kim","year":"2015","journal-title":"J. Infect."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00415-021-10701-8","article-title":"Cerebral mucormycosis: Neuroimaging findings and histopathological correlation","volume":"269","author":"Lersy","year":"2021","journal-title":"J. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e2019061","DOI":"10.4084\/mjhid.2019.061","article-title":"Rhino-Orbital-Cerebral Mucormycosis after Allogeneic Hematopoietic Stem Cell Transplantation and Isavuconazole Therapeutic Drug Monitoring during Intestinal Graft versus Host Disease","volume":"11","author":"Andreani","year":"2019","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1237125","DOI":"10.1155\/2022\/1237125","article-title":"Clinical Manifestations of Pulmonary Mucormycosis in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A 21-Case Series Report and Literature Review","volume":"2022","author":"Bao","year":"2022","journal-title":"Can. Respir. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.cmi.2020.12.035","article-title":"Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis","volume":"27","author":"Muthu","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1099\/jmm.0.000560","article-title":"Molecular diagnosis of rhino-orbito-cerebral mucormycosis from fresh tissue samples","volume":"66","author":"Zaman","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10096-005-0078-7","article-title":"Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples","volume":"25","author":"Rickerts","year":"2006","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"594.e1","DOI":"10.1016\/j.cmi.2015.01.017","article-title":"Molecular identification of Mucorales in human tissues: Contribution of PCR electrospray-ionization mass spectrometry","volume":"21","author":"Alanio","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1128\/JCM.00637-14","article-title":"Rapid detection and identification of mucormycetes in bronchoalveolar lavage samples from immunocompromised patients with pulmonary infiltrates by use of high-resolution melt analysis","volume":"52","author":"Lengerova","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e01655-17","DOI":"10.1128\/JCM.01655-17","article-title":"A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease","volume":"56","author":"Springer","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/cid\/ciab1066","article-title":"Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial","volume":"75","author":"Millon","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e00746-18","DOI":"10.1128\/JCM.00746-18","article-title":"PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis","volume":"56","author":"Baldin","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mercier, T., Reynders, M., Beuselinck, K., Guldentops, E., Maertens, J., and Lagrou, K. (2019). Serial Detection of Circulating Mucorales DNA in Invasive Mucormycosis: A Retrospective Multicenter Evaluation. J. Fungi, 5.","DOI":"10.3390\/jof5040113"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"810.e1","DOI":"10.1016\/j.cmi.2015.12.006","article-title":"Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: Retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)","volume":"22","author":"Millon","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Baldin, C., and Ibrahim, A.S. (2017). Molecular mechanisms of mucormycosis-The bitter and the sweet. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006408"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jinf.2022.11.020","article-title":"Utility of plasma cell-free DNA next-generation sequencing for diagnosis of infectious diseases in patients with hematological disorders","volume":"86","author":"Xu","year":"2023","journal-title":"J. Infect."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e3876","DOI":"10.1093\/cid\/ciaa1639","article-title":"Liquid Biopsy for Invasive Mold Infections in Hematopoietic Cell Transplant Recipients With Pneumonia Through Next-Generation Sequencing of Microbial Cell-Free DNA in Plasma","volume":"73","author":"Hill","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13613-020-00673-9","article-title":"Mucormycosis in intensive care unit: Surgery is a major prognostic factor in patients with hematological malignancy","volume":"10","author":"Claustre","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijantimicag.2019.01.002","article-title":"Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports","volume":"53","author":"Jeong","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.16329","article-title":"Mucormycosis in children with haematological malignancies is a salvageable disease: A report from the Israeli Study Group of Childhood Leukemia","volume":"189","author":"Elitzur","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejim.2022.03.008","article-title":"Survival in rhino-orbito-cerebral mucormycosis: An international, multicenter ID-IRI study","volume":"100","author":"Cag","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jiac.2019.08.003","article-title":"Surgical resection for persistent localized pulmonary fungal infection prior to allogeneic hematopoietic stem cell transplantation: Analysis of six cases","volume":"26","author":"Harada","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.21037\/acr.2019.11.02","article-title":"Pulmonary mucormycosis developed during acute myelogenous leukemia and successfully treated by surgical resection before blood stem cell transplantation","volume":"3","author":"Miura","year":"2019","journal-title":"AME Case Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"O336","DOI":"10.1111\/1469-0691.12408","article-title":"Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival","volume":"20","author":"Vironneau","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s15010-018-1149-x","article-title":"Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome","volume":"46","author":"Feng","year":"2018","journal-title":"Infection"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e28175","DOI":"10.1002\/pbc.28175","article-title":"Treatment of localized mucormycosis using nasal amphotericin B irrigation in pediatric oncology","volume":"67","author":"Khafagy","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.healun.2007.05.010","article-title":"Mucormycosis of the bronchial anastomosis: A case of successful medical treatment and historic review","volume":"26","author":"McGuire","year":"2007","journal-title":"J. Heart Lung Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/03007995.2021.2000779","article-title":"Cerebral mucormycosis: Intranasal route to deliver amphotericin B for effective management?","volume":"38","author":"Siddiqui","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/myc.13082","article-title":"Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"63","author":"Ruhnke","year":"2020","journal-title":"Mycoses"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/myc.13412","article-title":"Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study","volume":"65","author":"Thompson","year":"2022","journal-title":"Mycoses"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/mmy\/myz103","article-title":"Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system","volume":"58","author":"Schwartz","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12941-019-0311-3","article-title":"Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center","volume":"18","author":"Evans","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/myc.12851","article-title":"Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients","volume":"62","author":"DiPippo","year":"2019","journal-title":"Mycoses"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure\u2013response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e01643-18","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bolcato, L., Thiebaut-Bertrand, A., Stanke-Labesque, F., and Gautier-Veyret, E. (2022). Variability of Isavuconazole Trough Concentrations during Longitudinal Therapeutic Drug Monitoring. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195756"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/jac\/dkz344","article-title":"Matched-paired analysis of patients treated for invasive mucormycosis: Standard treatment versus posaconazole new formulations (MoveOn)","volume":"74","author":"Seidel","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: Focus on drugs without a clear recommendation","volume":"26","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: A pragmatic approach for adult and pediatric patients","volume":"15","author":"John","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/myc.13420","article-title":"Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID-19-associated mucormycosis in a real-life setting","volume":"65","author":"Patel","year":"2022","journal-title":"Mycoses"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"ofaa646","DOI":"10.1093\/ofid\/ofaa646","article-title":"Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents","volume":"8","author":"Miller","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ijantimicag.2018.08.005","article-title":"Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: The role of antifungal combination therapy","volume":"52","author":"Jenks","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/INF.0000000000002671","article-title":"Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients","volume":"39","author":"Bilavsky","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases","volume":"42","author":"Hare","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/myc.12911","article-title":"Posaconazole salvage therapy: The Posifi study","volume":"62","author":"Fortun","year":"2019","journal-title":"Mycoses"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4081\/idr.2018.7765","article-title":"Deferiprone as Adjunctive Treatment for Patients with Invasive Mucormycosis: A Retrospective Case Series","volume":"10","author":"Chitasombat","year":"2018","journal-title":"Infect. Dis. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/myc.12010","article-title":"Focus on invasive mucormycosis in paediatric haematology oncology patients: A series of 11 cases","volume":"56","author":"Rivier","year":"2013","journal-title":"Mycoses"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3109\/10428190109097768","article-title":"Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: Role of liposomal amphotericin B and GM-CSF","volume":"42","author":"Ma","year":"2001","journal-title":"Leuk. Lymphoma"},{"key":"ref_98","first-page":"e145","article-title":"Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor","volume":"32","author":"Palau","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"86","DOI":"10.28920\/dhm51.1.86-93","article-title":"Hyperbaric oxygen treatment: Results in seven patients with severe bacterial postoperative central nervous system infections and refractory mucormycosis","volume":"51","author":"Carvalho","year":"2021","journal-title":"Diving Hyperb. Med."},{"key":"ref_100","first-page":"355","article-title":"Hyperbaric oxygen in the treatment of invasive fungal infections: A single-center experience","volume":"9","author":"Segal","year":"2007","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0039-6257(05)80041-4","article-title":"Survival factors in rhino-orbital-cerebral mucormycosis","volume":"39","author":"Yohai","year":"1994","journal-title":"Surv. Ophthalmol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e00178-20","DOI":"10.1128\/AAC.00178-20","article-title":"Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus","volume":"64","author":"Gebremariam","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1128\/AAC.01437-15","article-title":"VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection","volume":"59","author":"Gebremariam","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1038\/s41467-020-17221-5","article-title":"Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14\/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e01941-17","DOI":"10.1128\/AAC.01941-17","article-title":"In Vitro and In Vivo Efficacy of a Novel and Long-Acting Fungicidal Azole, PC1244, on Aspergillus fumigatus Infection","volume":"62","author":"Colley","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/fmb-2022-0083","article-title":"Dual targeting of RdRps of SARS-CoV-2 and the mucormycosis-causing fungus: An in silico perspective","volume":"17","author":"Elfiky","year":"2022","journal-title":"Future Microbiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation","volume":"26","author":"Stern","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/myc.12924","article-title":"Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre","volume":"62","author":"Bowen","year":"2019","journal-title":"Mycoses"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/cis773","article-title":"Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: Results from the SEIFEM 2010-B registry","volume":"55","author":"Pagano","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/myc.12357","article-title":"Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: A single-centre retrospective study in Korea and clinical considerations","volume":"58","author":"Cho","year":"2015","journal-title":"Mycoses"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e00569-17","DOI":"10.1128\/AAC.00569-17","article-title":"Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections","volume":"61","author":"Chin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1093\/jac\/dkw322","article-title":"Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and\/or undergoing allogeneic haematopoietic stem cell transplantation: Off-trial experience","volume":"71","author":"Jeong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/AAC.02686-13","article-title":"Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease","volume":"58","author":"Maertens","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2019.04.006","article-title":"Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals","volume":"83","author":"Heimann","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: Results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/cid\/ciac230","article-title":"Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies","volume":"75","author":"Rausch","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13613-021-00818-4","article-title":"Poor outcome associated with mucormycosis in critically ill hematological patients: Results of a multicenter study","volume":"11","author":"Jestin","year":"2021","journal-title":"Ann. Intensive Care"}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/5\/592\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:38:15Z","timestamp":1760125095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/5\/592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":123,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jof9050592"],"URL":"https:\/\/doi.org\/10.3390\/jof9050592","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]}}}